198 related articles for article (PubMed ID: 30038391)
21. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.
Yoon KC; Park CS; You IC; Choi HJ; Lee KH; Im SK; Park HY; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):643-50. PubMed ID: 19850844
[TBL] [Abstract][Full Text] [Related]
22. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients.
Lee SY; Han SJ; Nam SM; Yoon SC; Ahn JM; Kim TI; Kim EK; Seo KY
Am J Ophthalmol; 2013 Aug; 156(2):247-253.e1. PubMed ID: 23752063
[TBL] [Abstract][Full Text] [Related]
23. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
Fava RA; Kennedy SM; Wood SG; Bolstad AI; Bienkowska J; Papandile A; Kelly JA; Mavragani CP; Gatumu M; Skarstein K; Browning JL
Arthritis Res Ther; 2011; 13(6):R182. PubMed ID: 22044682
[TBL] [Abstract][Full Text] [Related]
24. Human tear protein analysis enabled by an alkaline microfluidic homogeneous immunoassay.
Karns K; Herr AE
Anal Chem; 2011 Nov; 83(21):8115-22. PubMed ID: 21910436
[TBL] [Abstract][Full Text] [Related]
25. Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers.
Aqrawi LA; Galtung HK; Guerreiro EM; Øvstebø R; Thiede B; Utheim TP; Chen X; Utheim ØA; Palm Ø; Skarstein K; Jensen JL
Arthritis Res Ther; 2019 Jul; 21(1):181. PubMed ID: 31366407
[TBL] [Abstract][Full Text] [Related]
26. Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.
Meng Z; Klinngam W; Edman MC; Hamm-Alvarez SF
PLoS One; 2017; 12(9):e0184781. PubMed ID: 28902875
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Tear Osmolarity and Other Ocular Surface Parameters in Primary Sjögren's Syndrome.
Kim M; Kim HS; Na KS
Korean J Ophthalmol; 2017 Feb; 31(1):25-31. PubMed ID: 28243020
[TBL] [Abstract][Full Text] [Related]
28. Elevated tear interleukin-6 levels in patients with Sjögren syndrome.
Tishler M; Yaron I; Geyer O; Shirazi I; Naftaliev E; Yaron M
Ophthalmology; 1998 Dec; 105(12):2327-9. PubMed ID: 9855167
[TBL] [Abstract][Full Text] [Related]
29. Reduced Levels of Tear Lacritin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sjögren's Syndrome.
McNamara NA; Ge S; Lee SM; Enghauser AM; Kuehl L; Chen FY; Gallup M; McKown RL
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5237-5243. PubMed ID: 27711909
[TBL] [Abstract][Full Text] [Related]
30. [The evaluation of chosen cytokines in induction of ocular changes in Sjögren's syndrome of dry eye].
Zywalewska-Górna N; Mrugacz M; Bakunowicz-Lazarczyk A
Klin Oczna; 2007; 109(10-12):435-7. PubMed ID: 18488390
[TBL] [Abstract][Full Text] [Related]
31. Discovery and Verification of Sjögren's Syndrome Protein Biomarkers in Tears by Targeted LC-MRM.
Lépine M; Robert MC; Sleno L
J Proteome Res; 2024 Jun; 23(6):2219-2229. PubMed ID: 38682820
[TBL] [Abstract][Full Text] [Related]
32. IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer.
Nguyen CQ; Yin H; Lee BH; Chiorini JA; Peck AB
Lab Invest; 2011 Jan; 91(1):54-62. PubMed ID: 20856230
[TBL] [Abstract][Full Text] [Related]
33. Tear Osmolarity and Matrix Metallopeptidase-9 in Dry Eye Associated with Sjögren's Syndrome.
Kook KY; Jin R; Li L; Yoon HJ; Yoon KC
Korean J Ophthalmol; 2020 Jun; 34(3):179-186. PubMed ID: 32495525
[TBL] [Abstract][Full Text] [Related]
34. Lysine Demethylase 1B Promotes Tear Secretion Disorder in Sjogren's Syndrome by Regulating the PAX6/CLU Axis.
Liu S; Tang S; Yang G; Li Q
J Mol Neurosci; 2023 Jan; 73(1):28-38. PubMed ID: 36542318
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
Park E; Kim D; Lee SM; Jun HS
Oncotarget; 2017 Apr; 8(16):27240-27251. PubMed ID: 28460477
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
Hargreaves P; Daoudlarian D; Theron M; Kolb FA; Manchester Young M; Reis B; Tiaden A; Bannert B; Kyburz D; Manigold T
Arthritis Res Ther; 2019 Jul; 21(1):175. PubMed ID: 31319889
[TBL] [Abstract][Full Text] [Related]
37. A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.
Guo H; Lee C; Shah M; Janga SR; Edman MC; Klinngam W; Hamm-Alvarez SF; MacKay JA
J Control Release; 2018 Dec; 292():183-195. PubMed ID: 30359668
[TBL] [Abstract][Full Text] [Related]
38. MUC1 expression in Sjogren's syndrome, KCS, and control subjects.
Caffery B; Heynen ML; Joyce E; Jones L; Ritter R; Senchyna M
Mol Vis; 2010 Aug; 16():1720-7. PubMed ID: 20806091
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse.
Li X; Wu K; Edman M; Schenke-Layland K; MacVeigh-Aloni M; Janga SR; Schulz B; Hamm-Alvarez SF
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5019-29. PubMed ID: 20463324
[TBL] [Abstract][Full Text] [Related]
40. Differential Diagnosis of Sjögren Versus Non-Sjögren Dry Eye Through Tear Film Biomarkers.
Akpek EK; Wu HY; Karakus S; Zhang Q; Masli S
Cornea; 2020 Aug; 39(8):991-997. PubMed ID: 32195754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
